Why Eli Lilly Is Leaving Novo Nordisk in the Dust
Three years ago, Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) had about the same market value.…
Wegovy® injection becomes first GLP-1
The European Medicines Agency (EMA) has approved an update to the product information of Wegovy® injection, allowing it…
Wegovy® injection becomes first GLP-1 weight-loss treatment approved for 48-hour controlled-temperature delivery in the EU
Novo Nordisk A/S The European Medicines Agency (EMA) has approved an update to the product information of Wegovy®…
Wegovy® injection becomes first GLP-1 weight-loss treatment approved for 48-hour controlled-temperature delivery in the EU
Novo Nordisk A/S The European Medicines Agency (EMA) has approved an update to the product information of Wegovy®…
Why Novo Nordisk’s Pricing Shift Could Unlock a Much Larger Obesity Market
Over the past two years, Novo Nordisk (NYSE: NVO) has lost its lead in the anti-obesity space to…
LifeMD Offers Novo Nordisk’s Industry-First Wegovy® Telehealth Subscription Program
LifeMD, Inc. Delivering up to $1,200 in annual patient savings on branded GLP-1 therapy, expanding LifeMD’s collaboration with…
Why Novo Nordisk’s Pricing Shift Could Unlock a Much Larger Obesity Market
Key Points The market for weight loss drugs still has plenty of room to grow. Novo Nordisk’s new…
LifeMD Offers Novo Nordisk’s Industry-First Wegovy® Telehealth Subscription Program
LifeMD, Inc. Delivering up to $1,200 in annual patient savings on branded GLP-1 therapy, expanding LifeMD’s collaboration with…
Which Obesity Drug Stock Is the Better Buy?
Over the past year, the two leaders in the obesity drug market, Eli Lilly (NYSE: LLY) and Novo…
Novo Nordisk Weighs UBT251 Triple Agonist Against Semaglutide In Next Trials
Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million…
The FDA just approved triple the previous maximum dose of Wegovy
The U.S. Food and Drug Administration has approved a new dose of the GLP-1 class weight loss drug…
Wegovy® HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss
Novo Nordisk A/S Wegovy® HD demonstrated a mean weight loss of 20.7%1, and around one-third of patients achieved…